Literature DB >> 3025848

Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus.

B M Peterlin, P A Luciw, P J Barr, M D Walker.   

Abstract

The genome of human immunodeficiency virus encodes a protein that dramatically elevates amounts of viral proteins. The precise mechanism of this trans-activation remains to be established. It has been reported that trans-activation can occur without major changes in the levels of mRNA. We constructed recombinant plasmids containing those viral sequences required in cis for trans-activation linked to the chloramphenicol acetyltransferase gene. These plasmids were introduced into cultured cells in either the presence or absence of a second plasmid that directed expression of the viral trans-activator protein. Expression of the chloramphenicol acetyltransferase gene was measured at the level of protein (by enzymatic assay) and RNA (by ribonuclease protection and primer extension). Our results demonstrate that trans-activation is accompanied by large increases in mRNA levels; these increases may be sufficient to explain the elevated levels of trans-activated protein.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025848      PMCID: PMC387215          DOI: 10.1073/pnas.83.24.9734

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

2.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

3.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

4.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II.

Authors:  D J Slamon; K Shimotohno; M J Cline; D W Golde; I S Chen
Journal:  Science       Date:  1984-10-05       Impact factor: 47.728

6.  Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs.

Authors:  P A Krieg; D A Melton
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

7.  Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat.

Authors:  J Sodroski; C Rosen; F Wong-Staal; S Z Salahuddin; M Popovic; S Arya; R C Gallo; W A Haseltine
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

8.  Bovine leukemia virus long terminal repeat: a cell type-specific promoter.

Authors:  D Derse; S J Caradonna; J W Casey
Journal:  Science       Date:  1985-01-18       Impact factor: 47.728

9.  Molecular cloning of AIDS-associated retrovirus.

Authors:  P A Luciw; S J Potter; K Steimer; D Dina; J A Levy
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  143 in total

1.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Intronless mRNA transport elements may affect multiple steps of pre-mRNA processing.

Authors:  Y Huang; K M Wimler; G G Carmichael
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

3.  HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.

Authors:  B Bramlage; E Luzi; F Eckstein
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

4.  Exciton interaction in molecular beacons: a sensitive sensor for short range modifications of the nucleic acid structure.

Authors:  S Bernacchi; Y Mély
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

5.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

Review 6.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

7.  Functional comparison of the basic domains of the Tat proteins of human immunodeficiency virus types 1 and 2 in trans activation.

Authors:  B Elangovan; T Subramanian; G Chinnadurai
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.

Authors:  C M Drysdale; G N Pavlakis
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

9.  A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization.

Authors:  S Endo; S Kubota; H Siomi; A Adachi; S Oroszlan; M Maki; M Hatanaka
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

10.  Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA.

Authors:  A Gatignol; A Kumar; A Rabson; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.